Aligos receives $25m upfront as China HBV licence deal activates

Aligos Therapeutics has received a $25 million upfront payment from Xiamen Amoytop Biotech under an exclusive licence agreement covering pevifoscorvir sodium in Greater China. The South San Francisco-based company simultaneously announced that China's National Medical Products Administration (NMPA) had granted the candidate its Breakthrough Therapy Designation, a status that makes the drug eligible for priority review of a New Drug Application in China.

The deal's headline economics extend well beyond the upfront payment. Aligos is eligible to receive up to $420 million in clinical, regulatory and commercial milestone payments, plus tiered royalties described as high single-digit percentages on net sales in Amoytop's territories. Aligos retains full development and commercialisation rights in the United States, Europe, South Korea, Japan and all markets outside the licensed territories.

Deal mechanics and pipeline read-across

Lawrence Blatt, Chairman, President and Chief Executive of Aligos, said the joint steering committee with Amoytop is now in place and that the companies are working in parallel on a second asset. Aligos's antisense oligonucleotide (ASO) candidate ALG-170675 is expected to enter clinical trials in China in the third quarter of 2026, a timeline that would mark a meaningful step for the broader HBV pipeline at Aligos.

Breakthrough Therapy Designation under the NMPA framework broadly mirrors the FDA's equivalent mechanism: it is reserved for drugs treating serious diseases where preliminary clinical evidence suggests a meaningful advantage over existing therapies, and it compresses the review timeline for a subsequent NDA. The designation for pevifoscorvir sodium signals that Chinese regulators regard the preliminary efficacy data as sufficiently compelling to warrant expedited handling.

Pevifoscorvir sodium is a capsid assembly modulator (CAM), a class of antiviral agents that disrupts the hepatitis B virus replication cycle at a different stage from the nucleoside analogues that currently anchor chronic HBV therapy. The global chronic HBV market represents tens of millions of patients in China alone, making Greater China licensing one of the most commercially significant regional plays in the hepatitis space.

Competitive and regulatory context

The chronic HBV field is undergoing a significant transition, with multiple companies pursuing functional cure strategies that combine antivirals, RNA interference agents, and immune modulators. Roche, Gilead Sciences and Assembly Biosciences are among the larger players with HBV programmes at various clinical stages, while several specialist biotechs are advancing CAM-based and RNA-targeting approaches. The NMPA's Breakthrough Therapy Designation for pevifoscorvir sodium is a positive signal, though the key clinical test will be whether the candidate demonstrates durable virological suppression or, ultimately, a meaningful rate of surface antigen loss in combination regimens.

For Aligos, the $25 million upfront provides near-term capital to support its broader pipeline, which also includes programmes in metabolic dysfunction-associated steatohepatitis and obesity. The potential $420 million in milestones is back-loaded and contingent on clinical and regulatory progress, so investors will focus on the next data readouts and on whether ALG-170675 meets its Q3 2026 China clinic entry timeline as a guide to the pace of execution across the partnership.